Cogent Biosciences Inc (COGT)
8.91
-0.74
(-7.67%)
USD |
NASDAQ |
Nov 15, 16:00
9.27
+0.36
(+4.04%)
After-Hours: 20:00
Cogent Biosciences Enterprise Value: 807.10M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | 807.10M |
| November 13, 2024 | 889.19M |
| November 12, 2024 | 887.00M |
| November 11, 2024 | 889.19M |
| November 08, 2024 | 868.39M |
| November 07, 2024 | 850.88M |
| November 06, 2024 | 897.95M |
| November 05, 2024 | 844.31M |
| November 04, 2024 | 1.050B |
| November 01, 2024 | 1.034B |
| October 31, 2024 | 1.008B |
| October 30, 2024 | 1.065B |
| October 29, 2024 | 1.064B |
| October 28, 2024 | 1.052B |
| October 25, 2024 | 1.061B |
| October 24, 2024 | 1.065B |
| October 23, 2024 | 1.097B |
| October 22, 2024 | 1.091B |
| October 21, 2024 | 1.049B |
| October 18, 2024 | 1.053B |
| October 17, 2024 | 1.025B |
| October 16, 2024 | 993.17M |
| October 15, 2024 | 1.028B |
| October 14, 2024 | 988.79M |
| October 11, 2024 | 982.22M |
| Date | Value |
|---|---|
| October 10, 2024 | 964.71M |
| October 09, 2024 | 932.97M |
| October 08, 2024 | 938.44M |
| October 07, 2024 | 926.40M |
| October 04, 2024 | 966.90M |
| October 03, 2024 | 905.61M |
| October 02, 2024 | 924.21M |
| October 01, 2024 | 927.50M |
| September 30, 2024 | 932.97M |
| September 27, 2024 | 943.91M |
| September 26, 2024 | 943.91M |
| September 25, 2024 | 941.73M |
| September 24, 2024 | 948.29M |
| September 23, 2024 | 916.55M |
| September 20, 2024 | 952.67M |
| September 19, 2024 | 943.91M |
| September 18, 2024 | 905.61M |
| September 17, 2024 | 902.32M |
| September 16, 2024 | 935.16M |
| September 13, 2024 | 914.36M |
| September 12, 2024 | 874.96M |
| September 11, 2024 | 923.12M |
| September 10, 2024 | 919.84M |
| September 09, 2024 | 949.39M |
| September 06, 2024 | 896.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-30.24M
Minimum
Dec 11 2019
1.097B
Maximum
Oct 23 2024
377.41M
Average
254.23M
Median
Jan 11 2024
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.833M |
| Palatin Technologies Inc | 11.39M |
| iBio Inc | 5.346M |
| Theriva Biologics Inc | -13.34M |
| Oragenics Inc | 2.080M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -58.95M |
| Total Expenses (Quarterly) | 64.39M |
| EPS Diluted (Quarterly) | -0.59 |
| Earnings Yield | -27.83% |
| Normalized Earnings Yield | -28.56 |